AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PHVS · NASDAQ · Biotechnology

Pharvaris

Develops oral deucrictibant formulations to treat and prevent hereditary angioedema attacks.

$35.40

After-hours close+0.05 (+0.14%)

At close$35.35(−4.46%)

Something off on this page? Send us feedback.

Profile

Pharvaris N.V.PHVSHealth Care

Develops immediate-release and extended-release formulations of deucrictibant, an oral bradykinin B2-receptor antagonist, for on-demand treatment and prevention of hereditary angioedema attacks. The program's path is shaped by FDA review and clinical development.

Develops deucrictibant, an oral bradykinin B2-receptor antagonist for bradykinin-mediated angioedema. An immediate-release formulation is intended for on-demand HAE attack treatment, while an extended-release formulation is being developed for prophylaxis.

Operates as a rare-disease biopharmaceutical company concentrated on two formulations of the same molecule. The company is headquartered in Leiden, Netherlands, and its ordinary shares trade on Nasdaq.

Development has been shaped by an FDA clinical hold that was lifted in stages after a toxicology study. The immediate-release formulation now has an accepted U.S. NDA for HAE attacks, while the extended-release program remains in pivotal development.

Company facts

CEOBerndt Modig

ListedFeb 4, 2021

ExchangeNASDAQ

HeadquartersLeiden, Netherlands

CountryNetherlands

Employees129

CIK0001830487

ISINNL00150005Y4

Key statistics

Market cap$2.47B

EPS (ttm)−$3.13

P/E (ttm)−11.29

ROE-61.2%

P/B6.90

P/S0.00

Dividend yield—

Beta0.93vs XLV 0.60

Year to date +33.5% · Average volume (30d) 544.2K

Analysts

Price target, next 12 months$52.00+47.2%Median of 12 analysts · vs the Aug 28 close

ConsensusBuy11 of 12 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $35.32

High$74.00+109.5%

Median$52.00+47.2%

Low$40.00+13.3%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Prior target	Target
Aug 14, 2026	New Street	Target			$60
Aug 13, 2026	Guggenheim	Reiterate	Buy	$39	$40
Aug 13, 2026	HSBC	Upgrade	Overweight
Jul 15, 2026	Wells Fargo	Initiate	Overweight		$55
Jun 25, 2026	Morgan Stanley	Reiterate	Overweight	$41	$46

Earnings

EPS

Estimate−$0.84

ReportedDue Nov 11, 2026

Revenue

Estimate—

ReportedDue Nov 11, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 12, 2026Q2 FY26	−$0.75	−$0.81	−8.5%	—	—	—	+5.93%
May 12, 2026Q1 FY26	−$0.82	−$0.70	+14.8%	—	—	—	+5.41%
Apr 2, 2026Q4 FY25	−$0.71	−$0.85	−18.3%	—	—	—	−0.67%
Nov 12, 2025Q3 FY25	−$0.78	−$0.70	+10.3%	—	—	—	−6.01%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$0	$0	$0	$0	$0	$0
Gross profit	$0	$0	$0	$0	−$123.3K	$0
Operating income	$48.9M	−$46.8M	−$46.0M	−$55.2M	−$52.1M	−$58.8M
Net income	−$53.7M	−$52.7M	−$43.0M	−$54.2M	−$46.2M	−$55.4M
Diluted EPS	−$0.98	−$0.96	−$0.70	−$0.92	−$0.71	−$0.81
Gross margin	—	—	—	—	—	—
Operating margin	—	—	—	—	—	—

Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0

Balance sheet, Jun 30, 2026Cash & short-term investments $368.8M · Total debt $780.6K · Total assets $380.8M · Shareholders' equity $348.5M

Dividends

No dividends on record.

Ownership

Institutions 93.42%65.28M sharesInsiders 2.93%2.05M sharesOther 3.65%2.55M shares

Shares outstanding 69.88M · Float 33.19M · 47.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
FMR LLC	6.57M	9.40%	13F	Aug 13, 2026
General Atlantic, L.P.	6.55M	9.37%	13F	Aug 14, 2026
Foresite Capital Management Iv, LLC	4.78M	6.84%	13F	Aug 14, 2026
Venbio Partners LLC	4.64M	6.64%	13F	Aug 14, 2026
Viking Global Investors LP	3.65M	5.23%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 14, 2026	Berndt Modig	director, officer: Chief Executive Officer	−2,292	$34.77
Jul 13, 2026	Berndt Modig	director, officer: Chief Executive Officer	−2,292	$34.97
Jun 29, 2026	Anne Lesage	officer: Chief Early Development	−17,597	$35.06
Jun 30, 2026	Anne Lesage	officer: Chief Early Development	−58,575	$35.48
Jun 30, 2026	Johannes Gerardus Christiaan Petrus Schikan	director	−30,712	$35.49